×
About 1,147 results

ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center

Research & Reviews  557 results

Angioimmunoblastic T-cell lymphoma masquerading as granulomatous lymphadenitis: Fine ne...
https://doi.org/10.1002/dc.24726
Diagnostic Cytopathology; van den Akker TA, Chen H

Feb 25th, 2021 - Fine needle aspiration (FNA) is a minimally invasive technique used in the initial diagnosis of superficial lesions, including lymphadenopathy. Its benefit in lymph node pathology, however, is highly variable, especially in heterogeneous lymphopro...

Markers of Follicular Helper T Cells Are Occasionally Expressed in T-Cell or Histiocyte...
https://doi.org/10.1093/ajcp/aqaa249
American Journal of Clinical Pathology; Abukhiran I, Syrbu SI et. al.

Feb 24th, 2021 - Follicular helper T cell (TFH) markers are expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype (PTCL-TFH). However, differential expression and coexpression of these markers in benign and othe...

Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation ...
https://doi.org/10.3324/haematol.2020.265991
Haematologica Dobson R, Du PY et. al.

Feb 11th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma with T follicular helper phenotype (PTCL-TFH) are a group of complex clinicopathological entities that originate from TFH cells and share a similar mutation profile. Their di...

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmuno...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839364
Blood Advances; Lemonnier F, Safar V et. al.

Jan 26th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly population that has a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone  (CHOP) therapy. Lenalidomide, which has been ...

Acute Brain Stroke Evolution Detected by 18F-FDG PET/CT and MRI Justifies the Discordan...
https://doi.org/10.1097/RLU.0000000000003486
Clinical Nuclear Medicine; Fernández-Rodríguez P, Tamayo Carabaño D et. al.

Jan 14th, 2021 - A 50-year-old man with angioimmunoblastic T-cell lymphoma in complete response to treatment presented new hypermetabolic brain lesions on 18F-FDG PET/CT suggestive of malignancy. These findings were correlated by MRI that showed cortical-subcortic...

see more →

Clinicaltrials.gov  571 results

Angioimmunoblastic T-cell lymphoma masquerading as granulomatous lymphadenitis: Fine ne...
https://doi.org/10.1002/dc.24726
Diagnostic Cytopathology; van den Akker TA, Chen H

Feb 25th, 2021 - Fine needle aspiration (FNA) is a minimally invasive technique used in the initial diagnosis of superficial lesions, including lymphadenopathy. Its benefit in lymph node pathology, however, is highly variable, especially in heterogeneous lymphopro...

Markers of Follicular Helper T Cells Are Occasionally Expressed in T-Cell or Histiocyte...
https://doi.org/10.1093/ajcp/aqaa249
American Journal of Clinical Pathology; Abukhiran I, Syrbu SI et. al.

Feb 24th, 2021 - Follicular helper T cell (TFH) markers are expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype (PTCL-TFH). However, differential expression and coexpression of these markers in benign and othe...

Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation ...
https://doi.org/10.3324/haematol.2020.265991
Haematologica Dobson R, Du PY et. al.

Feb 11th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma with T follicular helper phenotype (PTCL-TFH) are a group of complex clinicopathological entities that originate from TFH cells and share a similar mutation profile. Their di...

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmuno...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839364
Blood Advances; Lemonnier F, Safar V et. al.

Jan 26th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly population that has a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone  (CHOP) therapy. Lenalidomide, which has been ...

Acute Brain Stroke Evolution Detected by 18F-FDG PET/CT and MRI Justifies the Discordan...
https://doi.org/10.1097/RLU.0000000000003486
Clinical Nuclear Medicine; Fernández-Rodríguez P, Tamayo Carabaño D et. al.

Jan 14th, 2021 - A 50-year-old man with angioimmunoblastic T-cell lymphoma in complete response to treatment presented new hypermetabolic brain lesions on 18F-FDG PET/CT suggestive of malignancy. These findings were correlated by MRI that showed cortical-subcortic...

see more →

News  19 results

Angioimmunoblastic T-cell Lymphoma: Patient Characteristics and Survival Outcomes
https://www.mdedge.com/fedprac/avaho/article/207820/lymphoma-plasma-cell-disorders/angioimmunoblastic-t-cell-lymphoma?channel=53
Ermann DA, Vardell VA et. al.

Sep 9th, 2019 - Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive malignancy, representing approximately 18. 5% of Peripheral T-cell lymphomas.

HDAC/HMA combo shows ‘remarkable’ activity in PTCL
https://www.mdedge.com/hematology-oncology/article/206189/t-cell-lymphomas/hdac/hma-combo-shows-remarkable-activity-ptcl?channel=303
Neil Osterweil

Aug 9th, 2019 - LUGANO, SWITZERLAND – A combination of 5-azacytidine and romidepsin showed promising activity in patients with peripheral T cell lymphomas, particularly angioimmunoblastic T-cell lymphoma (AITL) and primary cutaneous follicular helper T-cell lymph.

Cerdulatinib yields ‘encouraging’ results in CTCL, PTCL
https://www.mdedge.com/hematology-oncology/article/193975/lymphoma-plasma-cell-disorders/cerdulatinib-yields-encouraging?channel=39313
Jennifer Smith

Feb 6th, 2019 - LA JOLLA, CALIF. – The spleen tyrosine kinase/Janus kinase inhibitor cerdulatinib has demonstrated activity against relapsed and refractory T-cell lymphomas.

Combo emerges as bridge to transplant in rel/ref PTCL
https://www.mdedge.com/hematology-oncology/article/193912/lymphoma-plasma-cell-disorders/combo-emerges-bridge-transplant/page/0/1?channel=39313

Feb 5th, 2019 - Efficacy with romidepsin Among all evaluable PTCL patients in the romidepsin arm, the ORR was 59% (16/27), and the CR rate was 33% (9/27). Responses occurred in seven patients with PTCL not otherwise specified (NOS), six with angioimmunoblastic T-.

Four-drug combo shows durable responses in relapsed/refractory lymphomas
https://www.mdedge.com/hematology-oncology/article/193002/t-cell-lymphomas/four-drug-combo-shows-durable-responses-relapsed
Jennifer Smith

Jan 19th, 2019 - LA JOLLA, CALIF. — Results of a phase 1 trial suggest a four-drug combination can produce durable responses in patients with relapsed or refractory T- and B-cell lymphomas.

see more →